Trial Profile
An Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Three Dosing Regimens of Oral AT2220 in Patients With Pompe Disease
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 23 Aug 2018
Price :
$35
*
At a glance
- Drugs Duvoglustat (Primary)
- Indications Glycogen storage disease type II
- Focus Adverse reactions
- Sponsors Amicus Therapeutics
- 19 May 2014 New trial record